Clinical Trial Update: Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating baricitinib for new-onset juvenile dermatomyositis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Dermatomyositis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Juvenile Dermatomyositis | Phase 2 | Status: COMPLETED